乳腺癌与胃癌HER2免疫组化评分标准在子宫内膜癌评估中的比较
研究随机选取263例子宫内膜样腺癌、275例子宫浆液性癌和214例子宫癌肉瘤标本,由两名病理医师盲法分别用胃癌和乳腺癌标准行HER2免疫组化评分,并分析ERBB2 DNA扩增与RNA表达。两种标准在HER2阳性(95%)和阴性(88%)病例中一致性高,不一致主要见于胃癌标准判为不确定的病例;RNA表达有助于区分不确定与阴性病例。
要点
- 乳腺癌与胃癌HER2评分标准在子宫内膜癌中一致性高,不一致主要见于胃癌标准判为不确定的病例。
- RNA表达水平在不一致与阴性病例之间、阴性 vs 不确定病例之间均有显著差异。
- HER2阳性与子宫内膜样腺癌生存较差相关,与浆液性癌生存改善相关,癌肉瘤中无差异。
核心结论
- 乳腺癌与胃癌HER2评分标准在子宫内膜癌中一致性高,不一致主要见于不确定肿瘤。
- RNA表达可能有助于区分不确定与阴性病例。
- 需进一步研究确定DNA、RNA或蛋白水平的HER2改变能否预测对新一代HER2靶向治疗的反应。
研究设计与样本
- 随机选取263例子宫内膜样腺癌、275例子宫浆液性癌和214例子宫癌肉瘤标本。
- 既往HER2免疫组化切片由两名委员会认证病理医师盲法审阅,分别采用胃癌和乳腺癌标准评分。
- 通过DNA测序分析ERBB2拷贝数扩增,通过RNA测序分析ERBB2 RNA表达,采用非配对t检验判定统计学显著性。
主要发现
- 两种评分标准在HER2阳性病例中一致性为95%,在HER2阴性病例中一致性为88%。
- 不一致肿瘤中,乳腺癌标准判为阴性而胃癌标准判为不确定者占子宫内膜样腺癌89.7%、浆液性癌68.8%、癌肉瘤81.8%。
- RNA表达水平在不一致病例与阴性病例之间、阴性病例与不确定病例之间均有显著差异。
- HER2阳性与子宫内膜样腺癌生存较差相关,与浆液性癌生存改善相关,与癌肉瘤生存无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究确定DNA、RNA或蛋白水平的HER2改变能否预测对新一代HER2靶向治疗的反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunohistochemistry (IHC) testing is the primary method to determine HER2 status at many institutions, often with reflex to in situ hybridization (ISH). DNA- and RNA- based platforms are emerging for HER-2 assessment. While approved IHC algorithms exist for HER2 scoring in breast and gastric carcinomas, neither has been validated in endometrial cancer. This study seeks to compare them and evaluate patterns of DNA and RNA expression. METHODS: 263 endometrioid endometrial adenocarcinoma (EEA), 275 serous endometrial carcinoma (SEC), and 214 uterine carcinosarcoma (UCS) specimens were randomly selected. Previously stained HER2 IHC slides underwent blinded review by two board-certified pathologists and were scored utilizing gastric and breast criteria. Tumors were analyzed for ERBB2 copy number amplification by DNA sequencing and ERBB2 RNA expression by RNA sequencing. Statistical significance was determined using unpaired t-test. RESULTS: Concordance between scoring algorithms was high for HER2-positive (95 %) and HER2-negative (88 %) cases. Of discordant tumors, the majority (89.7 % of EEA, 68.8 % of SEC, and 81.8 % of UCS) were negative by breast but equivocal by gastric criteria. RNA expression levels were significantly different between discordant cases and negative cases and between negative and equivocal cases. HER2-positivity was associated with worse survival in EEC, improved in SEC, and no difference in UCS. CONCLUSIONS: Breast and gastric scoring criteria show high concordance in endometrial carcinoma, with discordance primarily in equivocal tumors. RNA expression may help stratify equivocal from negative cases. Further study is needed to determine whether HER2 alterations at the DNA, RNA, or protein level predict response to newer generation HER2-targeted therapies.
引用
- Furuya RL, Grither W, Evans MG, et al. Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma. Gynecol Oncol. 2025. PMID: 41232209. doi:10.1016/j.ygyno.2025.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。